Key Takeaways for Intuitive Surgical Stock as of July 2026
- Analysts rate Intuitive Surgical stock 16 buys / 9 holds / 2 sells with a mean target of $565, implying 42% upside from the current price of $398.
- TIKR’s mid-case model values Intuitive Surgical at $675 by December 2030, implying 70% total return, or 13% annualized.
- Q1 2026 adjusted EPS of $2.50 beat Street estimates of $2.11 by 19%, driven by 17% total procedure volume growth and EBIT margin expansion of 480 basis points year over year.
ISRG Beat Every Line in Q1 2026, and the Street Still Looks Like It Hasn’t Caught Up Yet
Intuitive Surgical (ISRG) delivered the sharpest earnings beat in recent memory when it reported Q1 2026 results on April 22, posting $2.77 billion in revenue, a 23% year-over-year increase that cleared the Street’s $2.62 billion estimate by 5.8%.
The scale of the outperformance matters because the Street had already baked in strong growth, meaning the beat was not a function of sandbagged consensus.
That revenue growth came from every direction. Da Vinci procedures grew 16% to 847,000 globally, while Ion procedures expanded 39% to 43,000. The single-port SP platform grew 68% year over year, with utilization in the U.S. up 22% against the same quarter last year.
What made the quarter structurally significant was the da Vinci 5 (dV5) utilization story. Chief Financial Officer Jamie Samath addressed it directly on the Q1 earnings call: “Da Vinci 5 utilization continues to exceed that of da Vinci Xi, driving U.S. utilization growth to 4%.” That comment has a specific implication: as dV5’s share of the installed base grows, the entire utilization floor for the U.S. franchise rises, compounding the procedure growth rate without requiring net new system placements.
Operating leverage confirmed the margin thesis. Non-GAAP EBIT of $1.077 billion came in 19.8% above the Street’s $899 million estimate, with EBIT margin reaching 38.9%, a 480 basis-point expansion year over year. The dV5 system hit contribution margins comparable to the Xi in Q1, ending the overhang from new-platform dilution that had weighed on gross margin guidance for four consecutive quarters.
Still, two headwinds deserve acknowledgment. China procedure growth remained below the corporate average amid lower tender volumes and domestic competition, and Japan posted below-average growth following reduced capital placements in 2025. Management guided for no resolution on Chinese reimbursement policy until 2027.
On balance, Intuitive raised full-year da Vinci procedure growth guidance from 13%-15% to 13.5%-15.5%, and lifted its non-GAAP gross profit margin forecast to 67.5%-68.5%, a 50-basis-point increase at the midpoint despite a residual 100-basis-point tariff impact baked into the revised range.
Wall Street Is Split on ISRG Stock Despite a Consensus Buy Rating
Twenty-nine of 31 analysts covering Intuitive Surgical stock rate it buy or outperform as of June 30, 2026, with only nine holds and two sells in the mix. The mean price target sits at $565, implying 42% upside from the June 30 closing price of $398, while the median target of $574 confirms the distribution skews bullishly.
Raymond James and TD Cowen trimmed their targets following the Q1 print, a divergence from a broader Street that has largely held its $600-plus targets even as ISRG stock has pulled back 14% year to date entering the Q1 session.
Wall Street Expects ISRG Revenue to Remain Above $11 Billion Through 2027
Revenue came in at $2.77 billion in Q1 2026, a 23% year-over-year increase against the prior-year comparable of $2.25 billion. The Street now models Q2 2026 revenue of $2.82 billion, implying 16% year-over-year growth, a meaningful step-down from the pace Intuitive just delivered.
Consensus builds gradually through the second half, with Q3 2026 revenue estimated at $2.89 billion and Q4 2026 at $3.21 billion, implying full-year 2026 revenue in the range of $11.6 billion at current run-rate estimates.
Looking into 2027, the Street models Q1 revenue at $3.10 billion and Q2 at $3.22 billion, implying year-over-year growth rates of 12% to 14% as dV5 penetration and OUS expansion continue to expand the base.
The unresolved condition is whether China and Japan normalize faster than the Street currently models. If procedure growth in those two markets recovers toward the 16% to 19% range Intuitive runs in Europe and India, the 13%-to-14% revenue growth estimates for 2027 look conservative by design, not by data.
ISRG Is Growing Revenue at Twice the Rate of Stryker and Nearly 4x Medtronic
Intuitive Surgical grew revenue 23% in Q1 2026. Stryker (SYK) grew 3% in the same period. Medtronic (MDT) grew 10%.
That gap is not a one-quarter anomaly. Over the trailing four quarters, ISRG averaged above 20% revenue growth while SYK averaged around 8% to 11% and MDT stayed in the single digits.
The forward estimates close the gap somewhat, with ISRG expected at 16% for Q2 2026, SYK at 9%, and MDT at 12%. But even at the Street’s more conservative ISRG forecast, Intuitive Surgical stock is priced as though that deceleration is permanent, not transitional.
TIKR’s $675 Target on ISRG Stock Holds If OUS Procedure Growth Accelerates
TIKR’s mid-case model values Intuitive Surgical at $675 by December 2030, implying 70% total return from the current price of $398, or 13% annualized over 4.5 years.
A 13% annualized return from a large-cap medical device company with $8 billion in net cash and a 39% non-GAAP operating margin represents above-market compounding at below-average financial risk, which is the kind of setup the model was built to surface.
The path to $675 does not require Intuitive to close the China gap or reaccelerate Japan. It requires dV5 utilization to continue outpacing Xi at the current spread, Ion to maintain its 39% procedure growth trajectory into the installed base, and SP to scale beyond its current 68% growth phase into a durable double-digit contributor. Each of those conditions found explicit support in Q1 data.
Should You Invest in Intuitive Surgical, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Intuitive Surgical, Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Intuitive Surgical, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze ISRG stock on TIKR for Free →
